MedTrace Logo

Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project

NCT00661154 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2012-08-10

No results posted yet for this study

Summary

To determine whether using a radiolabelled analog of 5-FU, \[18F\]-5-fluorouracil, for PET/CT imaging can visually demonstrate differential chemotherapy delivery to known tumor sites before and after administration of bevacizumab and determine the optimal timing of bevacizumab administration to maximize the chemotherapy delivery into the tumor for improved cancer treatment.

Conditions

Interventions

DRUG

Bevacizumab

2-12microCi IV injection

Sponsors & Collaborators

Principal Investigators

  • Dr Andrew Quon · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00661154 on ClinicalTrials.gov